| Purpose of the guideline: |
To address the therapeutic bottleneck of refractory immune hematologic diseases, the limited availability of many current drugs, and the advantages of mTOR inhibitors in the treatment of immune disorders, to improve the treatment of immune hematologic diseases in China, and to promote the standardization of clinical practice in order to help clinicians to treat immune hematologic diseases more accurately and, in particular, to optimize the use of mTOR inhibitors in the treatment of immune hematologic diseases.
|
